MK-8776, a CHK1 inhibitor, increases the sensitivity of p53-deficient NSCLC tumors to RT by disrupting G2/M arrest and inhibiting double-strand break repair [102]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.